FY2026 EPS Estimates for BLFS Increased by Analyst

BioLife Solutions, Inc. (NASDAQ:BLFS) – Analysts at Northland Securities raised their FY2026 earnings per share estimates for shares of BioLife Solutions in a report issued on Friday, February 27th. Northland Securities analyst C. Byrnes now expects that the medical equipment provider will post earnings of $0.12 per share for the year, up from their prior forecast of $0.10. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. Northland Securities also issued estimates for BioLife Solutions’ Q4 2026 earnings at $0.04 EPS.

A number of other analysts also recently weighed in on the stock. UBS Group restated a “buy” rating on shares of BioLife Solutions in a report on Monday, December 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, January 21st. HC Wainwright restated a “buy” rating and set a $32.00 price objective on shares of BioLife Solutions in a research report on Monday, December 29th. Zacks Research upgraded BioLife Solutions from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. Finally, Wall Street Zen raised BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

BioLife Solutions Stock Up 7.7%

BioLife Solutions stock opened at $24.20 on Monday. BioLife Solutions has a 52-week low of $19.10 and a 52-week high of $29.62. The firm’s fifty day moving average is $23.83 and its 200 day moving average is $25.21. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -219.98 and a beta of 1.90.

Institutional Investors Weigh In On BioLife Solutions

A number of hedge funds and other institutional investors have recently bought and sold shares of BLFS. Global Retirement Partners LLC purchased a new position in BioLife Solutions in the fourth quarter worth $30,000. Kemnay Advisory Services Inc. purchased a new stake in shares of BioLife Solutions during the 4th quarter valued at $35,000. Hantz Financial Services Inc. boosted its position in shares of BioLife Solutions by 54.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 659 shares in the last quarter. Quarry LP grew its stake in BioLife Solutions by 50.9% during the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 713 shares during the last quarter. Finally, Ameritas Investment Partners Inc. grew its stake in BioLife Solutions by 12.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after buying an additional 441 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Insiders Place Their Bets

In related news, Director Amy Duross sold 2,000 shares of the company’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $24.60, for a total transaction of $49,200.00. Following the completion of the sale, the director directly owned 18,687 shares in the company, valued at $459,700.20. This represents a 9.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Troy Wichterman sold 30,000 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $25.72, for a total transaction of $771,600.00. Following the sale, the chief financial officer directly owned 152,769 shares of the company’s stock, valued at approximately $3,929,218.68. The trade was a 16.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 37,802 shares of company stock valued at $967,191. 2.20% of the stock is owned by company insiders.

Trending Headlines about BioLife Solutions

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: Q4 results beat expectations — GAAP net income of $2.1M ($0.04/sh), revenue $24.8M (+20% YoY) and adjusted EBITDA of $6.9M (28% of revenue); management emphasized strong gross margins. BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations
• Positive Sentiment: Company set 2026 revenue guidance of $112.5M–$115.0M (implied 17–20% growth vs. 2025), above consensus — a clear near-term growth driver. BioLife Solutions outlines 17–20% revenue growth target for 2026 while expanding commercial customer mix
• Positive Sentiment: Quarterly EPS and revenue topped analyst estimates (EPS beat cited by Zacks and MarketBeat), reducing near-term earnings risk and supporting multiple expansion. BioLife Solutions Surpasses Q4 Earnings and Revenue Estimates (Zacks)
• Neutral Sentiment: Management discussed expansion of the commercial customer mix on the earnings call, which could raise upside if sustained but requires execution over 2026. BioLife Solutions Inc (BLFS) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Earnings call transcripts and full disclosures are available (InsiderMonkey / Seeking Alpha / Yahoo), useful for model updates but not new catalysts by themselves. Q4 2025 Earnings Call Transcript (InsiderMonkey)
• Negative Sentiment: Some third‑party summaries note a negative net‑margin metric and other minor discrepancies across outlets, which could create short-term confusion among investors until reconciled in filings. MarketBeat Q4 2025 Earnings Summary
• Negative Sentiment: Company did not provide clear EPS guidance in its FY2026 update (revenue guide provided but EPS line appeared blank in one release), which leaves earnings-per-share trajectory less certain. (Company disclosure)
• Neutral Sentiment: Reported short-interest data in public feeds showed anomalous zeros/NaN for February; no clear signal of a significant short-squeeze or bearish pressure at this time.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.